The Regnera Activa® technology is an innovative clinical approach to obtain autologous micrografts for the extraction of regenerative cells. At the end of the procedure, which lasts only 2 min, the micrografts are collected and processed. The regenerative role of micrografts was also reported in several in studies, and more important, displayed high positivity to mesenchymal stem cells markers. Therefore, the obtained autologous micrografts were identified as progenitor‐cell‐enriched micrografts. Preliminary study on patients that underwent hair transplantation reported that the autologous micrografts were able to promote continuous hair growth even 2 months after the procedure with a shortening of the dormant phase of the follicle and faster healing of the microwounds. Based on these evidence, the aim of this study was to demonstrate the efficacy and safety of the progenitor‐cell‐enriched micrograft in the management of hair loss. Following on from treatment, clinical evaluations were performed after 4, 6, and 12 months, along with histological and dermoscopic evaluation after 6 and 9 months from treatment highlighting the biological effect of the micrografts in a patient affected by androgenic alopecia.
For details on the treatment procedure please https://www.dynamicregenmedicine.co.uk/regenera-activa-hair-loss-treatment
The clinical evaluations of the use of the micrografts in the treatment of androgenic alopecia were performed after 4, 6, and 12 months from micrografts application reporting significant improvement of hair growth and density at all indicated times. The visual results are confirmed by TrichoScan® analysis where it can be observed an increase of total hair count and hair density accomplished by an increase and reduction of anagen and telogen phases, respectively, after the micrografts application. After 6 months of micrografts application, the number of hair follicles is higher. In this case, it is possible to visualise a significant improvement in the anagen III phase.
In addition to pharmacological treatment, there is a growing interest in alternative treatment options such as the use of growth factors or stem cells. However, the use of stem cells is complex from the regulatory prospective and often not permitted. The use of the Regenera Activa® treatment allows clinicians and researchers to disaggregate the patient’s own tissue, collecting progenitor‐cell‐enriched micrograft. Progenitors are a population of specialised regenerative cells, resident in many tissues in the body, that act following damage or injury. Such cells express some of the stem cells’ markers; however, differently from stem cells, progenitor cells are often unipotent. In this study, they have reported the effect of autologous micrografts on hair follicles restoration showing an improvement of hair growth and density after treatment. A recent study showed an increase of hair density after 6 months from treatment with human follicular cells isolated by the Regenera® device.
To confirm the effectiveness of autologous micrografts, other recent studies reported an increase of hair thickness together with a reduction of hair loss and a good patient’s level of satisfaction after micrografts application. Furthermore, the treatment was well tolerated concerning pain without side effects. In addition, the regenerative potential of the micrografts and the clinical efficacy have been already shown for bone regeneration, in the treatment of ulcers, wound dehiscences, and lastly for cartilage and cardiac regeneration.
Histological analysis performed in this study is suggestive for the role of micrografts in the development of new hair follicles. Based on the regenerative properties of micrografts, two probable mechanisms are thought for this effect. The first is the ability of micrografts to stimulate the hair follicular units reverting the process typical of androgenic alopecia. Second is the ability to induce the development of new hair follicles. After the micrografts application, it was reported an improvement in hair restoration accomplished by a positive patient’s subjective assessment. Taken together, these results are promising for major use of micrografts in the treatment of AGA.
Study 2019 https://www.ncbi.nlm.nih.gov/pubmed/31643084
GET IN TOUCH TO FIND OUT MORE OR SCHEDULE A FREE CONSULTATION
Don’t let the signs of ageing affect your confidence or get in the way of life. Schedule a FREE consultation with Dynamic Regenerative Medicine today, and let us treat your hair loss and provide you with full confidence again. We have clinics operating out of Solihull (Henley-In-Arden) and Birmingham.
Call us today 01564 330773